Where should your business play next?
Your next competitor might not make a medical device. Your next customer might not be a hospital. And your next wave of growth might not come from your next product.
The MedTech Growth Studio brings together 8–10 CEOs and senior leaders from non-competing, commercial-stage UK MedTech businesses. Over six months and six sessions, Xenergie's systemic methodology is applied to the question each of you is already facing: what does this business need to become next.
Built for leaders past the first approval, not before it.
A quick check before you book a conversation — the Studio works because every leader in the room is genuinely at the same stage.
Value in MedTech is expanding beyond the device.
Software, AI, data and connected technologies are embedding themselves in products and clinical workflows. Care is moving beyond traditional clinical settings. New commercial models are emerging. For a CEO with an approved product already in the market, the question is no longer just how to scale it — it's where the business plays next.
Embedding into diagnosis, decision-making and workflow — changing what the product is, and who else can build one.
Diagnosis and monitoring moving into primary care and the home — opening a path from single component to whole pathway.
Software, subscription and service revenue building value around the device, not replacing it.
Four connected lenses, applied to what your business becomes next.
A methodology overlay is what makes this systemic rather than simply social. Every leader examines their own version of the question through the same four lenses — a holistic view of the organisation, not a single fix.
The assumptions quietly shaping whether growth means a better device, or a different business.
Whether the team that got you to approval is the team that gets you to scale.
What the business and its people collectively believe growth beyond the device should look like.
The commercial, regulatory and organisational structures that shape what you can actually do next.
One cohort converges on a theme. Each leader brings their own version of the question.
Every participant's underlying strategic question is different — a platform choice, a market entry, a leadership gap. What the cohort shares is why this specific group is in the room together, which is why the journey runs on two tracks.
Where the cohort comes together to work “beyond the device” at the group level — sharing, challenging and supporting each other through structured hot seats and facilitated discussion.
Where each leader works the same question inside their own organisation, supported by digital tools, coaching calls and a rolling plan folded back into the next Studio session.
One journey, adapted from Xenergie's systemic transformation method.
Two sessions stay deliberately peer-only, protecting trust-building and the group's own working time; the other four bring in outside stimulus because the theme asks for it.
The cohort builds trust, names its own “beyond the device” question, and signs the participant agreement.
The three to five real strategic questions this shift raises — adoption, platform, model, geography — are named and validated by a practitioner who has seen the pattern before.
Each leader's question is reframed against what the rest of the cohort is seeing, surfacing patterns no single company would spot alone.
The cohort visits an organisation outside MedTech that has already made a comparable shift — software, data or platform-led growth — chosen deliberately so they see a different way of operating, not a mirror.
Shared future scenarios for UK MedTech are built from genuine horizon-scanning, and each leader's plan is pressure-tested against them.
Commitments are locked in publicly, progress is reviewed against named measures, and the cohort decides what it carries forward together.
What “beyond the device” looks like in practice.
Four patterns from Xenergie's UK MedTech market research — the kind of live, organisation-wide question this Studio is built to work on.
“A CE-marked diagnostics business, live in the NHS since last year, raised eight figures this summer to fund European and US expansion. The question: how does a single diagnostic product become a scalable platform?”
“A device-plus-service business already used in NHS pathways is weighing whether its next stage of growth comes from broader adoption, or from the data it's now generating at scale.”
“A regulated surgical technology company selling into 20+ countries is working out whether its growth engine should be procedure adoption, recurring consumables, or licensing — and whether its organisation is built for all three at once.”
“A platform business that started as a single surgical tool is now expanding into planning, guidance and partner deployment — and its leadership team is having to evolve as fast as the product.”
Illustrative patterns drawn from Xenergie's UK MedTech market research. Not confirmed participants.
Candour is engineered, not hoped for.
The conditions below are constant across every Studio, whatever the sector.
No direct competitor in, or likely to join, the same cohort. Candour depends on it.
Confidentiality, conduct and no solicitation, agreed in week one with stated consequences.
Enforced by the facilitator throughout, and briefed to every visiting expert.
Fit and willingness to share are tested in conversation, never assumed from a job title.
Where the work continues, supported by digital tools and coaching, not left to drift.
Small enough that everyone is exposed, large enough that the room holds real range.
What CEOs ask us before they join.
No. A peer forum builds trust but rarely has a diagnostic method underneath it; an accelerator or faculty programme teaches well but leaves the translation back into your organisation to you. A Studio is both at once, applied to your own live question.
Six sessions over six months, two of them in-person anchor days. Between sessions, the work happens inside your own organisation, at a pace you set, supported rather than policed.
No. Non-competing membership is a condition of every cohort, checked before anyone is confirmed, not left to chance.
We'll cover investment on the call once we understand your situation — it's discussed 1:1, not listed here, because cohort composition affects it.
Seven to nine other CEOs and senior leaders from non-competing, commercial-stage UK MedTech businesses, curated by Xenergie for genuine range and comparable stage — never disclosed before you've had your own intake call.
Commitments and measures are locked in publicly at session six. Many cohorts choose to keep meeting informally — that's their choice to make, not something Xenergie sells you into.
Founding UK MedTech cohort — applications close 23 October 2026.
Eight to ten places, one sector, one cohort. If the question of what your business becomes next deserves six months of focus, the next step is a conversation about whether this is the room for it.
Or contact Nigel Russell directly · nigel.russell@xenergie.com